Purchase Order 36C24624P0689
Award Date 2/15/24
Potential Completion Date 2/29/24
Potential Value $14K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Earth City, MO 63045, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Foundation Care LLC, a specialty pharmacy and subsidiary of Centene Corporation, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 (VISN 2) on February 4, 2026, to supply 60 units of Iclusig 15mg, a specialized chemotherapy medication used to treat blood disorders including chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The contract carries a ceiling value of $28,771.50 with an ultimate completion date of May 4,...
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Foundation Care LLC, a specialty pharmacy, to provide the drug Iclusig (ponatinib). The contract has a potential value of $110,424.15 and a completion date of September 30, 2022. Foundation Care LLC is a subsidiary of Centene Corporation, a for-profit organization. The contract does not have a set-aside designation. Through this and other federal contract awards,...
- Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $24,538.70 firm fixed price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 located in Palo Alto, California. The contract is for the provision of Iclusig (ponatinib), a medication used to treat certain types of leukemia and blood disorders. Performance will take place in Palo Alto and be completed by...
- This federal contract award to Foundation Care LLC, a full-service retail and specialty pharmacy, is for the drug Iclusig (ponatinib) for $115,946.48. The contract is a purchase order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21, with a completion date of September 30, 2021. The contract has no set-aside designation. Foundation Care LLC is a subsidiary of the for-profit organization Centene Corporation. Through this and over 60...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 8 to Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation. The $5,390.00 contract is for the delivery of pain management components, with an ultimate completion date of November 15, 2015. The contract does not have a set-aside designation. Foundation Care LLC is a critical supplier of specialized pharmaceutical products,...
- This federal contract award is for the supply of CHEMOTHERAPY MEDICATION, specifically the drug Iclusig (ponatinib) and other ponatinib medications, to the Federal Medical Center Lexington, a civilian agency under the Department of Veterans Affairs (VA). The $28,980.78 Firm Fixed Price award was granted to Foundation Care LLC, a specialty pharmacy and subsidiary of the larger healthcare organization Centene Corporation. The contract does not have a set-aside designation and is for a term...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $13,956.72 firm fixed price delivery order contract to Takeda Pharmaceuticals America, Inc. for ICLUSIG 15 MG. The contract was awarded on January 25, 2024 and is to be completed by January 30, 2024. It utilizes the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle, with performance taking place in Earth City, Missouri. Takeda Pharmaceuticals...
- This federal contract award was issued by the Veterans Integrated Service Network 5 (VISN 5), a division of the U.S. Department of Veterans Affairs (VA), to the prime contractor Takeda Pharmaceuticals America, Inc. The $13,956.72 firm-fixed-price delivery order is for the specialty oncology drug ICLUSIG 15 MG and was placed against Takeda's General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. The contract has an ultimate completion date of June...
- This is a firm-fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract, valued at $13,956.72, is for the delivery of ICLUSIG 10 & 15 MG, a specialty oncology medication, to various VA medical facilities across the country. The contract was awarded against Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals...
- Takeda Pharmaceuticals America, Inc., a foreign-owned biopharmaceutical manufacturer and subsidiary of Takeda Pharmaceutical Company Limited, was awarded a delivery order on July 31, 2025, for ICLUSIG 15 mg (ponatinib), an oncology medication, with a ceiling value of $14,197.39. This firm fixed-price delivery order was issued without a small business set-aside and is set to be completed by August 5, 2025. The contract will be performed in Earth City, Missouri, and is funded by Veterans...